Recombinant herpes simplex virus, method for producing the same, and its applications
JP2026519056APending Publication Date: 2026-06-11ZHONGYI (SUZHOU) BIOLOGICAL PHARMACEUTICAL CO LTD
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ZHONGYI (SUZHOU) BIOLOGICAL PHARMACEUTICAL CO LTD
- Filing Date
- 2023-11-08
- Publication Date
- 2026-06-11
AI Technical Summary
🎯Benefits of technology
【0005】 上記技術態様の有益な効果: (1)本発明はDPDを妨害するshRNAをHSV-CDに挿入し、HSV-CD-shDPD腫瘍溶解ウイルス( すなわち組換え単純ヘルペスウイルス)を構築する。該組換え単純ヘルペスウイルスはグ リオーマの代謝·侵襲·遊走を効果的に低下させると同時に、挿入されたCD遺伝子による プロドラッグ5-FCの代謝利用率を向上させ、CD遺伝子が変換した5-FU半減期及びグリオー マ細胞内での化学療法効率を増加させる、即ち外因性薬物の利用率を同時に向上させ、化 学療法薬の半減期及びグリオーマ細胞内での化学療法効率を増加させる。
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 1 Figure 2
Abstract
This invention relates to the field of genetic engineering. Recombinant herpes simplex virus and method for preparing the same. The recombinant herpes simplex virus and its uses are disclosed. The recombinant herpes simplex virus is a vector and a DPD gene. The vector includes a nucleotide sequence for reducing the expression level of the offspring. It is a herpes simplex virus that contains the CD gene but lacks the gene encoding ICP47. The insertion site of the nucleotide sequence for reducing the expression level of the DPD gene is the aforementioned vector This is the deletion site of the gene encoding ICP47 in the recombinant herpes simplex virus. Russ introduced shRNA that interferes with DPD into HSV-CD, thereby enabling the development of CD / 5-FC glioma cells. It enhances the killing ability against the target while simultaneously interfering with the metabolism of glioma cells.
Need to check novelty before this filing date? Find Prior Art